United Therapeutics Corporation - Common Stock · Transaction Oct 31, 2025 · Filed Nov 21, 2025 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · UTHR
+0.97% · +$5.22 · Vol 1.2M
After hours · updated 16:41:12 ET
United Therapeutics Corp
Biotechnology
$541.62
Follow $UTHR
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $UTHR by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredStale score · Mon Oct 5 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Wed 9:30 ET · UTHR
Methodologysnapshot unavailable for UTHR. Cause unavailable.
UTHR
United Therapeutics Corp
Stale score · Mon Oct 5 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Wed 9:30 ET
Upper range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
70/ 100
Veridion Score
Upper range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Stale score · Mon Oct 5 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Wed 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is UTHR moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About United Therapeutics Corp
PHARMACEUTICAL PREPARATIONSListed since
1999
Employees
1K
Country
US
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$537.19
Day high
$546.16
Day low
$527.33
Previous close
$536.40
52W high
$596.76
-9.24% from high
52W low
$415.34
70% of range
Market cap
$23B
P/E
17.70×
EPS
$27.96
Beta
-0.29
Shares out
42.9M
Volume
1.2M
1.40× rel vol
Avg volume
851.2K
VWAP
$540.41
Price history computed in-house
1W
+12.49%
1M
+11.08%
3M
-2.29%
1Y
+19.49%
YTD
+11.16%
SMA 50 $511.54 · above
SMA 200 $525.67 · above
52W position 70%
UTHR overview
Related filings and maps
Public disclosures
Congress activity in UTHR
3 filers · 2 buys · 4 sells (0 labeled S (partial)) · May 27, 2015 to Oct 31, 2025 · House 6 / Senate 0
All available history · Latest 5 of 6 lines · Read 2026-10-06T21:06:44.437Z
Official filing ↗
United Therapeutics Corporation - Common Stock · Transaction Oct 30, 2025 · Filed Nov 21, 2025 · $1,001 to $15,000
United Therapeutics Corporation - Common Stock · Transaction Oct 30, 2025 · Filed Nov 21, 2025 · $1,001 to $15,000
United Therapeutics Corporation - Common Stock · Transaction Jun 11, 2025 · Filed Aug 13, 2025 · $1,001 to $15,000
Donna ShalalaSell
UTHR · Transaction Mar 6, 2019 · Filed Apr 27, 2020 · $1,001 to $15,000
Federal contracts
UTHR contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for UTHR in this window.
Lobbying spend
UTHR lobbying filings, year to date.
Registered lobbying filings matched to United Therapeutics Corp.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for UTHR in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for UTHR.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.